|
"peck radosavljevic markus"的相關文件
顯示項目 1-3 / 3 (共1頁)
1
每頁顯示[10|25|50]項目
| 國立成功大學 |
2016-10 |
Phase II Studies with Refametinib or Refametinib Plus Sorafenib in Patients with Mutant RAS Hepatocellular Carcinoma (HCC)
|
Llovet, Josep M.;Merle, Philippe;Weiss, Karl Heinz;Yau, Thomas;Ross, Paul;Mazzaferro, Vincenzo;Blanc, Jean-Frederic;Ma, Yuk T.;Yen, Chia Jui;Kocsis, Judit;Choo, Su Pin;Sukeepaisarnjaroen, Watana;Gerolami, Rene;Dufour, Jean -Francois;Gane, Edward J.;Ryoo, Baek-Yeol;Peck-Radosavljevic, Markus;Dao, Thong;Yeo, Winnie;Lamlertthon, Wisut;Thongsawat, Satawat;Teufel, Michael;Krissel, Heiko;Lim, Ho Yeong |
| 國立臺灣大學 |
2015 |
Efficacy and safety of nintedanib (N) versus sorafenib (S) in Caucasian and Asian patients with advanced hepatocellular carcinoma (HCC): Pooled analysis of two randomized phase II trials.
|
Meyer, Tim; Palmer, Daniel H.; Chao, Yee; Choi, Caren; Deptala, Andrzej; Fartoux, Laetitia; Feng, Yin-Hsun; Graham, Janet Shirley; Hocke, Julia; Kim, Tae-You; Lin, Deng-Yn; Ma, Yuk Ting; Peck-Radosavljevic, Markus; Ross, Paul J.; Ryoo, Baek-Yeol; Wenz, Arne; Yen, Chia-Jui; Loembe, Arsene-Bienvenu; Cheng, Ann-Lii; 鄭安理 |
| 國立成功大學 |
2014-07-02 |
Effect of Everolimus on Survival in Advanced Hepatocellular Carcinoma After Failure of Sorafenib The EVOLVE-1 Randomized Clinical Trial
|
Zhu, Andrew X.; Kudo, Masatoshi; Assenat, Eric; Cattan, Stephane; Kang, Yoon-Koo; Lim, Ho Yeong; Poon, Ronnie T. P.; Blanc, Jean-Frederic; Vogel, Arndt; Chen, Chao-Long; Dorval, Etienne; Peck-Radosavljevic, Markus; Santoro, Armando; Daniele, Bruno; Furuse, Junji; Jappe, Annette; Perraud, Kevin; Anak, Oezlem; Sellami, Dalila B.; Chen, Li-Tzong |
顯示項目 1-3 / 3 (共1頁)
1
每頁顯示[10|25|50]項目
|
